Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 153,100

Document Document Title
WO/2019/008272A1
The present invention concerns a mutant strain of Sarcocystidae in which the two genes mic1 and mic3 are deleted, containing two specific recombination sites of an enzyme enabling a specific recombination in particular Cre recombinase, s...  
WO/2019/009979A1
The present invention is related to a dual promoter lentiviral vector and methods of use for the treatment of diseases and disorders, specifically lysosomal storage disorders.  
WO/2019/007869A1
The invention relates toa method of controlling the level of a polypeptide sequence comprising administering a polypeptide sequence fused to a ubiquitin targeting protein which comprises a minimal degron structural motif. In particular, ...  
WO/2019/008001A1
The present invention provides novel artificial nucleic acid molecules encoding at least one antigenic peptide or protein and at least one additional sequence preferably targeting the antigenic peptides or proteins to cellular compartmen...  
WO/2019/010429A1
The present disclosure relates to methods and kits for detecting pancreatic cancer (e.g., early stage pancreatic cancer, pre-cancerous lesions, and resectable pancreatic cancer) in a subject (e.g., human subject), including determining l...  
WO/2019/010301A1
The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAPβ, o...  
WO/2019/008438A1
The disclosure relates to modified apelin polypeptides having increased stability against kaliikrein, NEP and ACE2 degradation and/or potency relative to the native apelin-13 and apelin-17 polypeptides. Embodiments also disclose methods ...  
WO/2019/009604A2
The present invention relates to a superparamagnetic gold nanoparticle cluster-protein nanoparticle fusion body for magnetic resonance imaging and magnetic thermotherapy. According to the present invention, a superparamagnetic gold nanop...  
WO/2019/008052A1
The present invenetion concerns a DNA-replication-associated (Rep) protein comprising an amino acid sequence as depicted in SEQ ID NO:11 or 12; (b) a fragment of SEQ ID NOs:11 or 12 which is capable of binding an anti-Rep antibody specif...  
WO/2019/007509A1
This invention relates to novel recombinant botulinum neurotoxins serotype A exhibiting both (i) an increased duration of effect and (ii) a high specific biological activity. These novel recombinant botulinum neurotoxins comprise at leas...  
WO/2019/009819A1
The invention refers to a split superantigen, divided into two fragments that by itself do not exhibit biologic activity, only upon dimerization they regain T cell activity. Scope of the invention is a screening method for detection of e...  
WO/2019/008386A1
The present disclosure relates to use of an lgG2 anti-CD25 antibody, that does not inhibit IL-2 - CD25 interactions, with enhanced binding to activating Fcgamma Rs leading to effective depletion of tumor- infiltrating Treg cells and impr...  
WO/2019/010310A1
Disclosed are compositions and methods for the co-delivery of ribonucleic acids and interferon binding proteins. Compositions include mineral coated microparticles having a mineral layer, a ribonucleic acid, and an interferon binding pro...  
WO/2019/010191A1
The instant application provides a method for screening batches of soy hydrolysate for a desired amount of a component thereof, such as ornithine or putrescine, and selecting only those batches of soy hydrolysate that have a desired amou...  
WO/2019/008378A1
There is described a chimeric antigen receptor (CAR) which comprises an antigen binding domain which selectively binds to Receptor Tyrosine Kinase Like Orphan Receptor (ROR1), and its use. Also described is a T cell comprising the CAR an...  
WO/2019/006692A1
The present application provides a compound having a structure shown in general formula (I): R1-S1-YEKL-S2-R2 (I). The present application also provides a use of the compound.  
WO/2019/007974A1
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to ...  
WO/2019/008111A1
The present invention relates to novel adenovirus strains with a high immunogenicity and no pre-existing immunity in the general human population. The lack of pre-existing immunity is due to novel hypervariable regions in the adenoviral ...  
WO/2019/008157A1
The present invention concerns synthetic polynucleotides encoding a human fukutin- related protein (FKRP) wherein said polynucleotides contain at least a mutation avoiding supplementary transcript(s) generated from frameshift start codon...  
WO/2019/010201A1
In one embodiment, the invention' provides a chimeric antigen receptor (CAR) T cell which is conjugated to a bi-functional molecule which is specific for both an extracellular binding domain of the chimeric antigen receptor (CAR) T cell ...  
WO/2019/008335A1
The invention relates to a polypeptide, such as an Affimer polypeptide, comprising an amino acid sequence having at least 80% identity to amino acid residues 1 to 11, 13 to 15, 17 to 19, 21 to 25, 27 to 28, 35 to 37, 39, 41, 43 to 44, 46...  
WO/2019/007383A1
Disclosed are a peptide compound and an application thereof, and a composition containing the peptide compound. The present invention provides a peptide compound as represented by formula (1), and a pharmaceutically acceptable salt, a ta...  
WO/2019/006599A1
Provided are an HPV16 E7 40-74 antigen polypeptide, a coding gene of the antigen polypeptide, an expression vector for expressing the antigen polypeptide, and a host cell containing the expression vector. Also provided are uses of the co...  
WO/2019/008515A1
The invention pertains to novel hybrid peptidomimetics, pharmaceutical composition comprising thereof and use thereof in the treatment of neuropathic pain. The hybrid peptidomimetics according to the invention are comprised of two compon...  
WO/2019/008273A1
The present invention relates to a mutant strain of Sarcocystidae in which the function of the MIC1 protein and the function of the MIC3 protein are suppressed, for use in the prevention of infectious diseases in poultry.  
WO/2019/010181A1
Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that masks or otherwise blocks phosphatidylserine on the pathogen cell surface.  
WO/2019/006330A1
In human-human transplants, the organ recipient's serum is tested against a broad array of HLA (human leukocyte antigens) alleles. The current clinical assay almost performs a virtual crossmatch which allows elimination of incompatible d...  
WO/2019/005528A1
Described herein are methods and compositions related to induced alveolar epithelial type 2 cells (iAEC2s), e.g., artificially-produced epithelial type 2 cells.  
WO/2019/006169A1
Synthetic heme-containing molecules are described. The heme-containing molecules include a heme group bound to either two non-contiguous peptides or a single contiguous peptide via cysteine residues. Use of the synthetic heme-containing ...  
WO/2019/006374A1
Disclosed herein are partially ordered polypeptides, which include a plurality of disordered domains and a plurality of structured domains. The partially ordered polypeptides may have phase transition behavior and form aggregates at, abo...  
WO/2019/004799A1
The present invention relates to a VEGF-Grab protein-drug conjugate and a use thereof and, more particularly, to a conjugate of a fusion protein in which a VEGFR1 domain 2, a VEGFR1 domain 3, and an antibody fragment are connected and a ...  
WO/2019/006401A2
Provided herein are recombinant fusion polypeptides comprising one or more antigenic Wilms tumor protein (WT1) peptides, wherein at least one of the antigenic WT1 peptides is a heteroclitic mutant WT1 peptide (e.g., fused to a PEST-conta...  
WO/2019/002945A2
The present disclosure relates to a pro-drug peptide, or a salt thereof, having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group c...  
WO/2019/004811A1
The present invention relates to a chimeric protein comprising short sequences from some of the structural proteins in porcine respiratory and reproductive syndrome virus (PRRSV). The protein is used as capture antigen in an enzyme-linke...  
WO/2019/005955A1
The present disclosure provides compositions, methods, and kits related to enhanced reverse transcriptases comprising Eubacterium rectale maturase having one or more mutations.  
WO/2019/005948A1
Methods and pharmaceutical compositions for treating ischemic injury are provided. The methods include administering a therapeutically effective amount of a vascular matrix metalloproteinase 9 (MMP-9) inhibitor that reduces ischemic inju...  
WO/2019/006472A1
The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Ra Fc fusion protein and an antigen binding domain Fc fusion proteins. In some instances, the antigen binding domain binds to...  
WO/2019/001371A1
The present invention provides a method for preparing polylysine glyceride, uses of polylysine glyceride in the preparation of preservatives, and a method for preparing polylysine. The method for preparing polylysine glyceride comprises:...  
WO/2019/006348A1
The invention relates to fusions of coagulation Factor IX (FIX) and transferrin (Tf). These FIX-Tf fusion proteins can be administered orally, and are capable of reaching the systemic circulation by utilizing an endocytosis-dependent mec...  
WO/2019/006034A1
Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1...  
WO/2019/004446A1
The present invention addresses the problem of providing an excellent treatment agent for lysosomal storage disease. Provided is a treatment agent for lysosomal storage disease, containing a cellular structure that includes multiple bioc...  
WO/2019/004831A1
Novel nucleic acid sequences, vectors, modified cells, peptides and pharmaceutical compositions are provided that are useful in the treatment of human subjects having a ΔΝΡΜ 1 positive haematological malignancy. Corresponding methods...  
WO/2019/002590A1
The present invention relates to a transgenic non-human animal model for Neurofibromatosis type 1, wherein the Nf1 gene is specifically inactivated in BC cells and derivatives thereof.  
WO/2019/000223A1
The present application provides a chimeric antibody immune cell engager comprising a target cell binding domain that specifically binds to an antigen on a target cell, and an immune effector cell binding domain comprising an antigen-bin...  
WO/2019/003180A1
Disclosed herein are underlying aspects, including optimized media and growth conditions, for the enhanced secretion of a self-assembling extracellular self assembling native protein from a Yarrowia lipolytica strain through liquid cultu...  
WO/2019/006043A1
Provided herein are compositions and methods for retargeting recombinant viral capsid proteins/capsids/vectors, e.g., in vivo, with a multispecific binding molecule, such as a bispecific antibody, that specifically binds a heterologous e...  
WO/2019/004703A1
The present invention relates to a biomarker for epilepsy, a composition for diagnosis of epilepsy, an epilepsy-induced animal, and a composition for prevention or treatment of epilepsy. More particularly, the present invention relates t...  
WO/2019/005623A1
Analogs for CLR/RAMP receptor ligands are provided that have agonist, superagonist, antagonist, super-antagonist, or multiple receptor modulatng activity. The analogs can be selective for one or more CLR/RAMP receptors, or can be pan-spe...  
WO/2019/002893A1
The present invention relates to novel protein pores and their uses in analyte detection and characterisation. The invention particularly relates to an isolated pore complex formed by a CsgG-like pore and a modified CsgF peptide, or a ho...  
WO/2019/005871A1
Provided herein are, inter alia, methods, compositions, and kits for culturing and improving the quality of islet cells. Included are compositions and kits for the ex vivo culture of islets or islet cells as well as methods of making and...  

Matches 1 - 50 out of 153,100